1
|
Passos J, Lopes LB, Panitch A. Collagen-Binding Nanoparticles for Paclitaxel Encapsulation and Breast Cancer Treatment. ACS Biomater Sci Eng 2023; 9:6805-6820. [PMID: 37982792 PMCID: PMC10716849 DOI: 10.1021/acsbiomaterials.3c01332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 10/28/2023] [Accepted: 10/30/2023] [Indexed: 11/21/2023]
Abstract
In this study, we developed a novel hybrid collagen-binding nanocarrier for potential intraductal administration and local breast cancer treatment. The particles were formed by the encapsulation of nanostructured lipid carriers (NLCs) containing the cytotoxic drug paclitaxel within a shell of poly(N-isopropylacrylamide) (pNIPAM), and were functionalized with SILY, a peptide that binds to collagen type I (which is overexpressed in the mammary tumor microenvironment) to improve local retention and selectivity. The encapsulation of the NLCs in the pNIPAM shell increased nanoparticle size by approximately 140 nm, and after purification, a homogeneous system of hybrid nanoparticles (∼96%) was obtained. The nanoparticles exhibited high loading efficiency (<76%) and were capable of prolonging paclitaxel release for up to 120 h. SILY-modified nanoparticles showed the ability to bind to collagen-coated surfaces and naturally elaborated collagen. Hybrid nanoparticles presented cytotoxicity up to 3.7-fold higher than pNIPAM-only nanoparticles on mammary tumor cells cultured in monolayers. In spheroids, the increase in cytotoxicity was up to 1.8-fold. Compared to lipid nanoparticles, the hybrid nanoparticle modified with SILY increased the viability of nontumor breast cells by up to 1.59-fold in a coculture model, suggesting the effectiveness and safety of the system.
Collapse
Affiliation(s)
- Julia
Sapienza Passos
- Wallace
H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, United States
- Department
of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, SP 05508-000, Brazil
| | - Luciana B. Lopes
- Department
of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, SP 05508-000, Brazil
| | - Alyssa Panitch
- Wallace
H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, United States
| |
Collapse
|
2
|
Clinically Expired Platelet Concentrates as a Source of Extracellular Vesicles for Targeted Anti-Cancer Drug Delivery. Pharmaceutics 2023; 15:pharmaceutics15030953. [PMID: 36986815 PMCID: PMC10056378 DOI: 10.3390/pharmaceutics15030953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2023] [Revised: 02/25/2023] [Accepted: 03/13/2023] [Indexed: 03/17/2023] Open
Abstract
The short shelf life of platelet concentrates (PC) of up to 5–7 days leads to higher wastage due to expiry. To address this massive financial burden on the healthcare system, alternative applications for expired PC have emerged in recent years. Engineered nanocarriers functionalized with platelet membranes have shown excellent targeting abilities for tumor cells owing to their platelet membrane proteins. Nevertheless, synthetic drug delivery strategies have significant drawbacks that platelet-derived extracellular vesicles (pEV) can overcome. We investigated, for the first time, the use of pEV as a carrier of the anti-breast cancer drug paclitaxel, considering it as an appealing alternative to improve the therapeutic potential of expired PC. The pEV released during PC storage showed a typical EV size distribution profile (100–300 nm) with a cup-shaped morphology. Paclitaxel-loaded pEV showed significant anti-cancer effects in vitro, as demonstrated by their anti-migratory (>30%), anti-angiogenic (>30%), and anti-invasive (>70%) properties in distinct cells found in the breast tumor microenvironment. We provide evidence for a novel application for expired PC by suggesting that the field of tumor treatment research may be broadened by the use of natural carriers.
Collapse
|
3
|
Nierenberg D, Flores O, Fox D, Sip YYL, Finn C, Ghozlan H, Cox A, McKinstry KK, Zhai L, Khaled AR. Polymeric Nanoparticles with a Sera-Derived Coating for Efficient Cancer Cell Uptake and Killing. ACS OMEGA 2021; 6:5591-5606. [PMID: 33681599 PMCID: PMC7931424 DOI: 10.1021/acsomega.0c05998] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Accepted: 02/11/2021] [Indexed: 06/12/2023]
Abstract
Nanoparticle-mediated cancer drug delivery remains an inefficient process. The protein corona formed on nanoparticles (NPs) controls their biological identity and, if optimized, could enhance cancer cell uptake. In this study, a hyperbranched polyester polymer (HBPE) was synthesized from diethyl malonate and used to generate NPs that were subsequently coated with normal sera (NS) collected from mice. Cellular uptake of NS-treated HBPE-NPs was compared to PEGylated HBPE-NPs and was assessed using MDA-MB-231 triple-negative breast cancer (TNBC) cells as well as endothelial and monocytic cell lines. NS-treated HBPE-NPs were taken up by TNBC cells more efficiently than PEGylated HBPE-NPs, while evasion of monocyte uptake was comparable. NS coatings facilitated cancer cell uptake of HBPE-NPs, even after prior interaction of the particles with an endothelial layer. NS-treated HBPE-NPs were not inherently toxic, did not induce the migration of endothelial cells that could lead to angiogenesis, and could efficiently deliver cytotoxic doses of paclitaxel (taxol) to TNBC cells. These findings suggest that HBPE-NPs may adsorb select sera proteins that improve uptake by cancer cells, and such NPs could be used to advance the discovery of novel factors that improve the bioavailability and tissue distribution of drug-loaded polymeric NPs.
Collapse
Affiliation(s)
- Daniel Nierenberg
- Burnett
School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32827, United States
| | - Orielyz Flores
- Burnett
School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32827, United States
| | - David Fox
- Nanotechnology
Science Center, University of Central Florida, Orlando, Florida 32826, United States
- Department
of Chemistry, College of Science, University
of Central Florida, Orlando, Florida 32816, United States
| | - Yuen Yee Li Sip
- Nanotechnology
Science Center, University of Central Florida, Orlando, Florida 32826, United States
- Department
of Materials Science and Engineering, College of Engineering and Computer
Science, University of Central Florida, Orlando, Florida 32816, United States
| | - Caroline Finn
- Burnett
School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32827, United States
| | - Heba Ghozlan
- Burnett
School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32827, United States
| | - Amanda Cox
- Burnett
School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32827, United States
| | - K. Kai McKinstry
- Burnett
School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32827, United States
| | - Lei Zhai
- Nanotechnology
Science Center, University of Central Florida, Orlando, Florida 32826, United States
- Department
of Materials Science and Engineering, College of Engineering and Computer
Science, University of Central Florida, Orlando, Florida 32816, United States
- Department
of Chemistry, College of Science, University
of Central Florida, Orlando, Florida 32816, United States
| | - Annette R. Khaled
- Burnett
School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32827, United States
| |
Collapse
|